A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens
Abstract Previously, cytotoxic drugs were the only option for patients with non‐small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a breakthrough in the treatment of advanced NSCLC and have improved survival r...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15041 |
| _version_ | 1797691684425826304 |
|---|---|
| author | Satoshi Tanaka Nobuaki Yoshimura Ryo Asakawa Satoshi Tobita Moto Yaga Kiyonobu Ueno |
| author_facet | Satoshi Tanaka Nobuaki Yoshimura Ryo Asakawa Satoshi Tobita Moto Yaga Kiyonobu Ueno |
| author_sort | Satoshi Tanaka |
| collection | DOAJ |
| description | Abstract Previously, cytotoxic drugs were the only option for patients with non‐small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a breakthrough in the treatment of advanced NSCLC and have improved survival rates. In addition, advances in next‐generation sequencing (NGS) have revealed the landscape of genomic alterations in patients with different cancers, aiding in the development of new molecularly targeted drugs. The patient reported here was a 54‐year‐old woman with left lower lung adenocarcinoma. The lung cancer was staged as T2aN3M1a stageIVA 11 years ago. She had received seven regimens of chemotherapy for 11 years. Among these, pemetrexed (PEM) regimens particularly showed long‐term effects totaling more than 5 years. We performed NGS after disease progression of the seventh treatment. NGS revealed CD74‐ROS1 fusion and she was treated with entrectinib. She has been taking entrectinib for over 20 months now. Herein, we report a rare case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by NGS that achieved long‐term survival with cytotoxic drugs, especially PEM regimens. In patients showing favorable clinical response to PEM regimens, physicians should consider testing for ROS1/ALK rearrangement. |
| first_indexed | 2024-03-12T02:16:45Z |
| format | Article |
| id | doaj.art-0b677e61d0a441c2a1a51cdc45a6a716 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-12T02:16:45Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-0b677e61d0a441c2a1a51cdc45a6a7162023-09-06T07:35:33ZengWileyThoracic Cancer1759-77061759-77142023-09-0114252618262110.1111/1759-7714.15041A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimensSatoshi Tanaka0Nobuaki Yoshimura1Ryo Asakawa2Satoshi Tobita3Moto Yaga4Kiyonobu Ueno5Department of Respiratory Medicine Osaka General Medical Center Osaka JapanDepartment of Respiratory Medicine Osaka General Medical Center Osaka JapanDepartment of Respiratory Medicine Osaka General Medical Center Osaka JapanDepartment of Respiratory Medicine Osaka General Medical Center Osaka JapanDepartment of Respiratory Medicine Osaka General Medical Center Osaka JapanDepartment of Respiratory Medicine Osaka General Medical Center Osaka JapanAbstract Previously, cytotoxic drugs were the only option for patients with non‐small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a breakthrough in the treatment of advanced NSCLC and have improved survival rates. In addition, advances in next‐generation sequencing (NGS) have revealed the landscape of genomic alterations in patients with different cancers, aiding in the development of new molecularly targeted drugs. The patient reported here was a 54‐year‐old woman with left lower lung adenocarcinoma. The lung cancer was staged as T2aN3M1a stageIVA 11 years ago. She had received seven regimens of chemotherapy for 11 years. Among these, pemetrexed (PEM) regimens particularly showed long‐term effects totaling more than 5 years. We performed NGS after disease progression of the seventh treatment. NGS revealed CD74‐ROS1 fusion and she was treated with entrectinib. She has been taking entrectinib for over 20 months now. Herein, we report a rare case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by NGS that achieved long‐term survival with cytotoxic drugs, especially PEM regimens. In patients showing favorable clinical response to PEM regimens, physicians should consider testing for ROS1/ALK rearrangement.https://doi.org/10.1111/1759-7714.15041long‐term survivallung adenocarcinomanext‐generation sequencingpemetrexedROS1 rearrangement |
| spellingShingle | Satoshi Tanaka Nobuaki Yoshimura Ryo Asakawa Satoshi Tobita Moto Yaga Kiyonobu Ueno A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens Thoracic Cancer long‐term survival lung adenocarcinoma next‐generation sequencing pemetrexed ROS1 rearrangement |
| title | A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens |
| title_full | A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens |
| title_fullStr | A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens |
| title_full_unstemmed | A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens |
| title_short | A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens |
| title_sort | case of cd74 ros1 positive lung adenocarcinoma diagnosed by next generation sequencing achieved long term survival with pemetrexed regimens |
| topic | long‐term survival lung adenocarcinoma next‐generation sequencing pemetrexed ROS1 rearrangement |
| url | https://doi.org/10.1111/1759-7714.15041 |
| work_keys_str_mv | AT satoshitanaka acaseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT nobuakiyoshimura acaseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT ryoasakawa acaseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT satoshitobita acaseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT motoyaga acaseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT kiyonobuueno acaseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT satoshitanaka caseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT nobuakiyoshimura caseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT ryoasakawa caseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT satoshitobita caseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT motoyaga caseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens AT kiyonobuueno caseofcd74ros1positivelungadenocarcinomadiagnosedbynextgenerationsequencingachievedlongtermsurvivalwithpemetrexedregimens |